The variation between Angiotensin-Converting Enzyme Inhibitors (A.C.E. Inhibitors) and Angiotensin II Receptors Antagonists (A.II R.A.), in C.O.P.Ds. and Hypertensive patients
Abstract
This study reflects that both A.C.E. inhibitors and A.IIR.A. had been reduced the hypertension in a total 281 patients, that A.C.E. inhibitors had significant results 175(62.27%), more than A.IIR.A. 106(27.72%) in treatment of hypertension in those C.O.P.D. patients with ages ranged between (40-70) years old. Also, we found that there was some degree of serum lipids reduction in those patients which were treated by either A.C.E. inhibitors 22(8.185%), or by A.IIR.A.24(8.540%), with no significant different results in this reduction of serum lipids in both A.C.E. inhibitors and A.IIR.A..References
-Laurence D.R., Bennett P.N. et al, Clinical Pharmacology, "Sulphonamide and sulphonamide combination" (Churchill Ling stone), 9th Ed. 2003, 137.
- Mary J. Mycek, Richard A. Harvey, et al, "Lippincott's illustrated Reviews, uses of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Antagonist", 2nd Ed, 1997, 156-157, 187.
-Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, The trial of treatment of heart failure in with A.T.1 blockers ,"Clinical study ,randomized trail"; Lancet, 1999;353;611-16.
- Cooper ME., "Pathogenesis, Prevention, and treatment of diabetic nephropathy"; Lancet; 1998; 352; 213-219.
-Lyme J. babanor F., Awerian J., Kemory I. et al; "The side effects of ACE inhibitors and angiotensin 2 receptor antagonist in different population"; BMJ;1999;Vol.213; issue 8077; 132-145.
-Defar M., Sawyer D., Jonson S., et al, The risky adverse effect of ACE inhibitors and β-blockers" M.E.P.P.O; www.meppo.com, 2011; 664-667.
--Mary J. Mycek, Richard A. Harvey, et al,Lippincotts illustrated reviews pharmacology, "Antihypertensive drugs, 2nd Ed. 1997, 179.
--Leonard G. Gomella, Steen A. Hasit, Aimee G. Adams, "Clinician Pocket Drugs Reference" –Copyright Ed., 2011, 146 and 161.
- Spence J.D., Westlie M. R. Breslow J.L. et al; Pathogenesis of atherosclerosis and its complications. effects of antihypertensive drugs, J Hum Hyper tens 3 1989 63-68.
-Becaterina R., Basta G., Schulz et all, The incidence of A.C.E. inhibitors in Chronic obstructive pulmonary disease patients, British journal of pharmacology; vol. 325;2012; 204-10.
- Keane WF, Kasiske BL, O'Donnell MP: Hyperlipidemia following induction of metabolic disorders in animals with different, that deal with different antihypertensive agents; Am J.
-Mark K., John L., et al" Serum lipids a analysis after treatment with different types of antihypertensive agents" British journal of pharmacology, 1998, Vol. 218, 96-152.
-Keider S., Smith J., Breslow J.L., et al "The angiotensin 11 receptor antagonist, Losartan, inhibit LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice, Biochem Biophys Res Commun 236, 1997, 622-625.
- Spence J.D., Westlie M. R. Breslow J.L., Namelon K., et al,"The role of β-blockers or ACE inhibitors and angiotensin II antagonist for reduction of serum lipid, in atherosclerotics", BMJ,Vol.325, 1999, issue 801, 201-2.
